KR-67500

KR-67500 is a selective 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor developed as a therapeutic candidate for metabolic disorders and bone diseases. The compound works by selectively inhibiting 11β-HSD1, an enzyme responsible for local regeneration of active glucocorticoids from inactive forms. In preclinical studies, KR-67500 demonstrated anti-diabetic, anti-adipogenic, and anti-osteoporotic activities. The drug improved glucose tolerance and insulin sensitivity in diet-induced obese mice, suppressed cortisone-induced adipocyte differentiation, enhanced bone morphogenetic protein 2 (BMP2)-induced osteoblastogenesis, and inhibited receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis. The compound showed potential as a multi-faceted treatment for type 2 diabetes mellitus, obesity, and osteoporosis, representing a novel therapeutic approach targeting the glucocorticoid metabolism pathway.[1][4][13][15]